Literature DB >> 24057895

How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Kui Toh Gerard Leong1, Henry Krum.   

Abstract

Resistant hypertension poses significant health concerns. There are strong demands for new safe therapeutics to control resistant hypertension, while addressing its common causes, specifically poor compliance to lifelong polypharmacy, lifestyle modification and physician inertia. The sympathetic nervous system plays a significant pathophysiological role in hypertension. Surgical sympathectomy for blood pressure reduction is an old but extremely efficacious therapeutic concept, since abandoned, with the dawn of safer contemporary pharmacology era. Recently, clinical studies have revealed promising results for safe and sustained blood pressure reduction with percutaneous renal sympathetic denervation. This is a novel, minimally-invasive, device-based therapy, specifically targeting and ablating the renal artery nerves with radiofrequency waves, without permanent implantation. There are also reported additional benefits in related comorbidities, such as impaired glucose metabolism, renal impairment, left ventricular hypertrophy, heart failure, and others. This review will focus on how selective renal sympathetic denervation works, as well as its present and potential therapeutic indications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24057895     DOI: 10.1007/s11886-013-0414-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  76 in total

1.  First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.

Authors:  Tom Mabin; Marc Sapoval; Vincent Cabane; Joanne Stemmett; Mano Iyer
Journal:  EuroIntervention       Date:  2012-05-15       Impact factor: 6.534

2.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

3.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.

Authors:  A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

4.  Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study.

Authors:  Stefano Del Pace; Guido Parodi; Benedetta Bellandi; Linda Zampini; Francesco Venditti; Matilde Ardito; David Antoniucci; Gian Franco Gensini
Journal:  Clin Res Cardiol       Date:  2011-01-08       Impact factor: 5.460

Review 5.  Renal denervation in human hypertension: mechanisms, current findings, and future prospects.

Authors:  Markus P Schlaich; Dagmara Hering; Paul A Sobotka; Henry Krum; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 6.  What causes sudden death in heart failure?

Authors:  Gordon F Tomaselli; Douglas P Zipes
Journal:  Circ Res       Date:  2004-10-15       Impact factor: 17.367

Review 7.  Noradrenaline release and the pathophysiology of primary human hypertension.

Authors:  M Esler; G Jennings; G Lambert
Journal:  Am J Hypertens       Date:  1989-03       Impact factor: 2.689

8.  Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.

Authors:  Markus P Schlaich; Elisabeth Lambert; David M Kaye; Zygmunt Krozowski; Duncan J Campbell; Gavin Lambert; Jacqui Hastings; Anuradha Aggarwal; Murray D Esler
Journal:  Hypertension       Date:  2003-11-10       Impact factor: 10.190

9.  Hypertension following renal transplantation: the role of the host's kidney.

Authors:  M I McHugh; H Tanboga; R Marcen; F Liano; V Robson; R Wilkinson
Journal:  Q J Med       Date:  1980

10.  Evidence against reinnervation of cardiac vagal afferents after human orthotopic cardiac transplantation.

Authors:  J A Arrowood; E Goudreau; A J Minisi; A B Davis; P K Mohanty
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.